NASDAQ:SNGX - Soligenix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.21 -0.03 (-2.42 %) (As of 12/13/2019 12:09 PM ET) Add Compare Today's Range$1.21Now: $1.21▼$1.2150-Day Range$0.89MA: $1.00▼$1.2852-Week Range$0.65Now: $1.21▼$1.39Volume305 shsAverage Volume104,270 shsMarket Capitalization$24.99 millionP/E RatioN/ADividend YieldN/ABeta1.32 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNGX Previous Symbol CUSIPN/A CIK812796 Webhttp://www.soligenix.com/ Phone609-538-8200Debt Debt-to-Equity Ratio0.01 Current Ratio1.42 Quick Ratio1.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.24 million Price / Sales4.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book3.18Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-8,900,000.00 Net Margins-193.39% Return on Equity-212.69% Return on Assets-101.28%Miscellaneous Employees14 Outstanding Shares20,650,000Market Cap$24.99 million Next Earnings Date3/24/2020 (Estimated) OptionableNot Optionable Receive SNGX News and Ratings via Email Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SNGX Rates by TradingView Soligenix (NASDAQ:SNGX) Frequently Asked Questions What is Soligenix's stock symbol? Soligenix trades on the NASDAQ under the ticker symbol "SNGX." How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $1.30 million during the quarter, compared to analysts' expectations of $1.40 million. Soligenix had a negative return on equity of 212.69% and a negative net margin of 193.39%. View Soligenix's Earnings History. When is Soligenix's next earnings date? Soligenix is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Soligenix. What price target have analysts set for SNGX? 1 analysts have issued 12-month target prices for Soligenix's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Soligenix's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 230.6% from the stock's current price. View Analyst Price Targets for Soligenix. What is the consensus analysts' recommendation for Soligenix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soligenix. Has Soligenix been receiving favorable news coverage? Media coverage about SNGX stock has been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Soligenix earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Soligenix. Are investors shorting Soligenix? Soligenix saw a drop in short interest in the month of November. As of November 29th, there was short interest totalling 92,600 shares, a drop of 58.8% from the November 14th total of 224,900 shares. Based on an average daily volume of 65,200 shares, the short-interest ratio is currently 1.4 days. Currently, 0.5% of the shares of the company are short sold. View Soligenix's Current Options Chain. Who are some of Soligenix's key competitors? Some companies that are related to Soligenix include Strongbridge Biopharma (SBBP), Helix Biopharma (HBPCF), Aduro BioTech (ADRO), Marinus Pharmaceuticals (MRNS), TFF Pharmaceuticals (TFFP), Synlogic (SYBX), Oramed Pharmaceuticals (ORMP), Immunic (IMUX), Vaccinex (VCNX), ESSA Pharma (EPIX), Inflarx (IFRX), Millendo Therapeutics (MLND), vTv Therapeutics (VTVT), Cumberland Pharmaceuticals (CPIX) and Otonomy (OTIC). What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include Synergy Pharmaceuticals (SGYP), Viking Therapeutics (VKTX), Energy Transfer LP Unit (ET), T2 Biosystems (TTOO), Verastem (VSTM), Celsion (CLSN), Gilead Sciences (GILD), ImmunoGen (IMGN), Tetraphase Pharmaceuticals (TTPH) and Zynerba Pharmaceuticals (ZYNE). Who are Soligenix's key executives? Soligenix's management team includes the folowing people: Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 53)Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 65)Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 47)Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 67)Mr. Richard L. Dunning, Exec. Officer (Age 73) How do I buy shares of Soligenix? Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Soligenix's stock price today? One share of SNGX stock can currently be purchased for approximately $1.21. How big of a company is Soligenix? Soligenix has a market capitalization of $24.99 million and generates $5.24 million in revenue each year. The biopharmaceutical company earns $-8,900,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Soligenix employs 14 workers across the globe.View Additional Information About Soligenix. What is Soligenix's official website? The official website for Soligenix is http://www.soligenix.com/. How can I contact Soligenix? Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected] MarketBeat Community Rating for Soligenix (NASDAQ SNGX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 237 (Vote Outperform)Underperform Votes: 174 (Vote Underperform)Total Votes: 411MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: Pattern Day Trader - What is the PDT Rule?
